June 19, 2018 / 8:14 PM / a month ago

BRIEF-FDA Allows Label For Novartis' Drug Cosentyx To Include Psoriatic Arthritis Benefit

June 19 (Reuters) - Novartis AG:

* NOVARTIS RECEIVES FDA APPROVAL FOR INCLUSION OF NEW EVIDENCE THAT COSENTYX® INHIBITS PROGRESSION OF JOINT STRUCTURAL DAMAGE IN PSORIATIC ARTHRITIS

* NOVARTIS - RECEIVES FDA APPROVAL FOR INCLUSION OF NEW EVIDENCE THAT COSENTYX INHIBITS PROGRESSION OF JOINT STRUCTURAL DAMAGE IN PSORIATIC ARTHRITIS

* NOVARTIS-NEW PRESCRIBING INFORMATION TO INCLUDE DATA DEMONSTRATING COSENTYX SLOWS PROGRESSION OF JOINT STRUCTURAL DAMAGE ASSOCIATED WITH PSA AT WEEK 24

* NOVARTIS AG - DATA WILL BE ADDED TO DRUG'S PRESCRIBING INFORMATION AND IS EFFECTIVE IN U.S. IMMEDIATELY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below